Latest News-Henlius Mediaroom_Page

Henlius' 4th Biologics: Bevacizumab Biosimilar Hanbeitai Approved by National Medical Products Administration

SHANGHAI, Dec. 4, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that beva...

2021-12-04 01:51 5471

Henlius Novel Anti PD-L1/TIGIT Bispecific Antibody Received Clinical Trial Approval in Australia

SHANGHAI, Nov. 25, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the...

2021-11-25 17:27 2951

2021 CSCO | Henlius will Release Four Oral Presentations of Two Upcoming Commercial Products: Novel anti-PD-1 mAb Serplulimab and Bevacizumab Biosimilar

SHANGHAI, Sept. 18, 2021 /PRNewswire/ -- The 24th Annual Meeting of Chinese Society of Clinical Onc...

2021-09-18 20:00 11515

The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for First-Line Treatment of sqNSCLC Accepted by China's NMPA, Phase 3 MRCT Met its Primary Endpoint

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that th...

2021-09-17 20:00 4048

Henlius reports half-year (H1) 2021 results, outlines remarkable growth in commercialization and needs-driven innovation

SHANGHAI, Aug. 18, 2021 /PRNewswire/ -- Henlius (2696.HK) announced Half-Year (H1) results endedJun...

2021-08-18 21:35 3686

The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review

SHANGHAI, April 23, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that th...

2021-04-23 15:00 1873

The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review

SHANGHAI, April 22, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that th...

2021-04-22 21:47 3057

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint

SHANGHAI, March 29, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that th...

2021-03-29 08:27 3667

Making Most out of Launched Products Fueling Diversified Innovation through Integrated Platform

SHANGHAI, March 28, 2021 /PRNewswire/ -- Henlius (2696.HK) announced the financial results for the ...

2021-03-28 11:16 2624

Henlius Adalimumab Biosimilar Approved by NMPA

SHANGHAI, Dec. 8, 2020 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the ...

2020-12-08 21:00 2563

China's First Trastuzumab Biosimilar Approved by NMPA

SHANGHAI, Aug. 17, 2020 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced onAugust...

2020-08-17 08:00 3952

Henlius and Accord Healthcare Receive EMA Approval for Zercepac®, trastuzumab biosimilar

SHANGHAI, July 30, 2020 /PRNewswire/ -- The European Commission (EC) has approved Shanghai Henlius ...

2020-07-30 08:00 5211

Henlius and Accord Receive Positive CHMP Opinion for Oncology Biosimilar, HLX02 (Trastuzumab)

SHANGHAI, June 1, 2020 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) and Accord Healthca...

2020-06-01 13:48 3218

Henlius receives EU GMP Certificate for HLX02 (Trastuzumab for Injection)

SHANGHAI, April 23, 2020 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that th...

2020-04-23 22:02 3292

Henlius successfully held its fourth Scientific Advisory Board (SAB) meeting

SHANGHAI, Feb. 18, 2020 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK, Henlius), a global...

2020-02-18 21:59 6350

Henlius HLX01 (Rituximab Injection) Wins "Biosimilar Initiative of the Year" at Global Generics & Biosimilars Awards 2019

SHANGHAI, Nov. 7, 2019 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), a leading biopharm...

2019-11-07 01:00 2260

European Medicines Agency Accepted First "China-Developed" Biosimilar - Henlius HLX02 Marketing Authorization Application for Review

* First China biosimilar conducted a multi-center, international phase 3 clinical trial * First...

2019-06-21 20:29 2627